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Purpose/Objective: Transrectal Ultrasound (US) is the standard 
imaging modality for High-Dose-Rate brachytherapy (HDR-BT) in 
prostate cancer. The treatment is most often delivered with the US 
probe positioned in the rectum, in order to maintain the same patient 
set-up as during the US treatment planning. However, it is an open 
question whether removal of the probe before HDR-BT delivery may 
be an advantage in terms of rectal dose. The objective of this study 
was to compare rectum dose with and without the US probe in place. 
Materials and Methods: T2-weighted (T2W)-MRI based HDR-BT 
treatment planning was performed after transrectal US guided needle 
implantation for 6 fractions of HDR-BT in 3 prostate cancer patients. 
HDR-BT was delivered in 2 fractions of each 8.5 Gy preceded by 46 Gy 
given in 23 fractions of external beam radiotherapy (EBRT). T2W-MRIs 
and US images were co-registered based on the HDR-BT needle 
implant (figure 1). The same optimized treatment plan based on MRI 
contouring was applied on both MR- and US images. Rectum dose-
volume parameters were evaluated for the 2 scenarios; 1) with the US 
probe in place (US images) and 2) with the US probe removed (MR 
images). Doses were evaluated as the total EBRT+BT EQD2 (α/β = 3 for 
rectum). Furthermore, absolute volumes irradiated to at least 70 Gy 
and 60 Gy (total EBRT+BT) were evaluated. 
 
 
Results: The mean rectum doses D5cm3, D2cm3 and D0.1cm3 were 
consistently higher for the case where the US probe was present in the 
rectum during the HDR-BT delivery (increase of 4, 5 and 13 Gy, 
respectively) (table 1). Furthermore, V70Gy (probe in: 2.2 ± 1.1 Gy; 
probe out: 0.8 ± 0.5 Gy) and V60Gy (probe in: 8.7 ± 1.8 Gy; probe out: 
4.7 ± 1.4 Gy) decreased when the US probe was removed. Qualitative 
evaluation of the rectal anatomy with (US) and without (MR) probe 
indicated that the distance between prostate and rectum was 
increased at the base- as well as at the apex regions after removal of 
the US probe (figure 1). 
 
  
Conclusions: Our results indicate that by removing the US probe from 
the patient during the delivery of HDR-BT the dose to rectum can be 
reduced. This study did not evaluate potential deformations of target 
and consequential impact on target dose induced by the US probe 
removal. The advantages of decreased rectal dose by probe removal 
may compromise target dose in the setting of US guided prostate HDR-
BT and should be further evaluated. 
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Purpose/Objective: LDR prostate brachytherapy using permanent 
iodine125 seeds has been offered to men with low volume prostate 
cancer in Wellington since 2001, and 500 men had been treated with 
145Gy by 2010. 
Materials and Methods: We initially employed the treatment 
technique as developed and reported by the Seattle Prostate 
Institute. Dose distribution based on a post-implant pelvic CT scan at 
4-6 weeks was routinely calculated for quality assurance purposes, 
and perceived deficiencies in dosimetry led to modifications in the 
way we planned and positioned future implants. Adjustments included 
a gradual reduction in margins as the implants improved technically, 
and changes in seed distribution to prevent crowding of seeds at the 
prostate apex. 
Results: Median follow up was 34 months (range 1-119 months). 23 
men developed biochemical failure (BF), and only two of these had 
detectable local failure. The risk of BF at 5 years was 6.7%. The only 
tumour characteristic that predicted a significantly higher chance of 
BF was an initial PSA > 10, whereas Gleason score, clinical stage, and 
percentage positive biopsies were not predictive. The D90 (<90, 90-
125, >125) had no detectable effect on the risk of BF. There have 
been 11 deaths in total, but only two from prostate cancer. 
There were 26 grade three side effects. Acute (within six months) 
grade three side effects were largely urinary, with 20 men (4%) 
requiring temporary urinary catheterisation. There was one case of 
protracted rectal ulceration. Delayed grade three side effects were 
defined as those occurring after 6 months that required operative 
intervention. There were three cases of urethral stricture, and two of 
chronic rectal ulceration, one leading to the development of a recto-
urethral fistula. The risk of any grade three side effect was 
independent of the D90 (<90, 90-125, >125) and the V150 (<40, 40-65, 
>65). The V150 was >65 in 56 (11%) implants. 
155 men (31%) required a PDE5 inhibitor for erectile dysfunction after 
their implant (but not before) and only 62 (11%) found this treatment 
ineffective. The risk of erectile dysfunction was not affected by the 
V150 (<40, 40-65, >65) and younger men (≤60 years) were not at 
significantly lower risk of this side effect. 
Conclusions: Biochemical control and toxicity in this series are at 
least as good as those reported elsewhere.  
A low D90 & V150 did not predict for an increased chance of BF, as 
some series have shown. This is possibly due to there being too few 
events (23) in our series to allow meaningful statistical comparisons 
involving small sub-groups (<90 D90; 70 [14%] implants, and <40 V150; 
73 [14.6%] implants). Inaccuracies in defining the prostate volume on 
CT may have been a factor, but it is also possible that the dose-effect 
range for low volume cancer is below the minimum dose achieved 
with the great majority of implants. High D90 and V150 did not 
predict for an increased risk of grade 3 toxicity, similar to other 
reported series. Side effect risk may be more a function of the 
prostate size, baseline urinary symptoms and implant technique rather 
than the dose distribution achieved by the implant.  
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Purpose/Objective: To determine whether dosimetric parameters, 
biochemical control of prostate cancer and late toxicity in patients 
with large prostate glands is different to those with smaller sized 
glands after treatment with high dose-rate brachytherapy alone (HDR-
BT). 
Materials and Methods: From November 2003 to July 2009, 164 
patients with locally advanced prostate carcinoma were sequentially 
enrolled and treated with 34 or 36 Gy (in 4 fractions) and 31.5 Gy (in 3 
fractions) of 192Ir HDR-BT alone. Median follow up is 71 months. 
Prostate gland size was not considered a selection criteria in this 
study. Estimates of freedom from biochemical relapse (FFbR) and late 
morbidity, stratified by median clinical target volume (CTV), were 
obtained using the Kaplan-Meier method and differences compared 
using the Mantel-Cox log-rank test. Hazard Ratios were obtained using 
Cox’s Proportional Hazard Model. Differences in IPSS scores grouped 
by median CTV were compared using Fisher's Exact Test (2-tail p). 
Results: Median CTV volume was 60 cc (range 15 to 208 cc). Dose-
volume parameters D90 and V100 (i.e. minimum dose to 90% of the 
